4.5 Article

Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis

期刊

JOURNAL OF RHEUMATOLOGY
卷 38, 期 9, 页码 1925-1930

出版社

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.110060

关键词

SCLERODERMA; GASTROINTESTINAL TRACT; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; PSYCHOMETRICS

资金

  1. Canadian Institutes of Health Research
  2. Scleroderma Society of Canada
  3. Actelion Pharmaceuticals
  4. Pfizer Inc.
  5. Inova Diagnostics Inc.

向作者/读者索取更多资源

Objective. The University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium GI Tract Instrument (UCLA SCTC GITI) was recently developed to measure gastrointestinal tract disease in systemic sclerosis (SSc). Our study assesses the internal consistency and validity of the instrument in a different population than was used in the original study. Methods. A sample of 113 consecutive patients with SSc from the Canadian Scleroderma Research Group (CSRG) Registry completed the UCLA SCTC GITI, a self-administered questionnaire with 7 scales and an overall score. Reliability was evaluated using Cronbach's alpha coefficient and validity was determined by testing multiple constructs. Results. Our subjects were slightly older than the original cohort, and had less formal education and less diffuse cutaneous disease. The overall score of the instrument correlated well with the GI scale of the Health Assessment Questionnaire for the Spondyloarthropathies (GI-S-HAQ; r = 0.58, p < 0.001) and the total number of GI symptoms (r = 0.77, p < 0.001). Each subscale correlated well with the GI-S-HAQ. The individual scales and the overall score were able to differentiate between categorical groupings of the GI-S-HAQ. The scale scores differentiated well those patients with clinical involvement of the corresponding GI problem. Multiple linear regression adjusting for age, disease duration, sex, and ethnicity showed that the UCLA SCTC GITI had a significant association with both the physical component summary and the mental component summary of the Medical Outcomes Study Short-Form 36 questionnaire. Conclusion. Our study confirms that the UCLA SCTC GITI version 2.0 will be a useful tool for assessing the role of GI involvement in SSc, even in a population with substantially different characteristics than the subjects originally tested. (First Release July I 2011; J Rheumatol 2011;38:1925-30; doi:10.3899/jrheum.110060)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据